Wednesday, May 8, 2019

MabVax Therapeutics' Assets Acquired By German Company

The antibody assets and infrastructure of San Diego-based MabVax Therapeutics has been acquired by a German company, BioNTech SE, according to BioNTech SE. Financial details of the acquisition were not annoucned. BioNTech SE is acquiring those assets out of the Chapter 11 bankruptcy proceedings for MabVax. According to BioNTech SE, it itends to establish a new, research facility in S

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.

---